Table 1 Characteristics of studies included in the meta-analysis
Author [Ref.] | Year | Country | Cancer category | Case no. | Cancer stage | Design type | Primary treatment option | Optimal cut-off for AFR/FPR | No. > against No. < (cut-off) | Prognostic outcomes | Hazard ratio (95% CI) | Data origin | Follow-up period (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chen et al. [22] | 2019 | China | Colorectal cancer | 430 | Metastatic | Prospective | Mixed modality but targeted therapy | 9.9 by X-tile (AFR) | NR | OS, PFS | OS(U),1.73 (1.35–2.21), Cohort 1 | Crude | More than 36 |
PFS(U),1.85 (1.29–2.65), Cohort 1 | Crude | ||||||||||||
Chen et al. [22] | 2019 | China | Colorectal cancer | 77 | Metastatic | Prospective | Radiochemotherapy | 9.9 by X-tile (AFR) | NR | OS, PFS | OS(U), 1.75 (0.93–3.31), Cohort 2 | Crude | More than 36 |
PFS(U),1.43 (0.84–2.42), Cohort 2 | Crude | ||||||||||||
Yu et al. [23] | 2019 | China | Ovarian cancer | 313 | Advanced | Retrospective | Surgery plus chemotherapy | 7.78 by ROC (AFR) | 162/151 | OS, PFS | OS(U), 2.50 (1.44–4.09) | Crude | At least 12 |
OS(M),2.19 (1.18–3.67) | Crude | ||||||||||||
PFS(U),1.56 (1.21–2.05) | Crude | ||||||||||||
PFS(M),1.38 (1.04–1.82) | Crude | ||||||||||||
Zhang et al. [24] | 2019 | China | Colorectal cancer | 71 | Metastatic | Retrospective | Chemotherapy | 10.63 by ROC (AFR) | 23/48 | PFS | PFS(U),1.91 (1.14–3.20) | Crude | Median 6.67 (1.86-27.17) |
Li et al. [25] | 2019 | China | Ovarian cancer | 186 | I–IV (FIGO) | Retrospective | Surgical resection | Score = 0 (AFR) | 148/38 | OS | OS(U),1.92 (1.56–2.23), Subgroup 1 | Crude | Median 45.5 (2.0-45.5) |
OS(M),1.05 (1.02–1.63), Subgroup 1 | Crude | ||||||||||||
OS(U),2.53 (1.36–4.71), Subgroup 2 | Crude | ||||||||||||
OS(M),2.13 (1.14–3.26),Subgroup 2 | Crude | ||||||||||||
Ying et al. [26] | 2019 | China | NSCLC | 270 | III–IV (TNM) | Retrospective | Chemotherapy | 8.02 by ROC (AFR) | 119/151 | OS, PFS | OS(U),1.93 (1.28–2.98) | Crude | Up to 60 |
OS(M),1.79 (1.11–2.59) | Crude | ||||||||||||
PFS (U), 2.07 (1.32–3.12) | Crude | ||||||||||||
PFS (M),1.80 (1.09-2.78) | Crude | ||||||||||||
Du [27] | 2019 | China | Gallbladder cancer | 220 | Metastatic | Retrospective | Chemotherapy mainly | 15.45 by X-tile (AFR) | NR | OS | OS(U),1.97 (0.96–3.67) | Crude | More than 36 |
OS(M),0.89 (0.46–1.73) | Crude | ||||||||||||
Wang [28] | 2019 | China | CRLM | 452 | Metastatic | Retrospective | Surgical resection | 13.16 by X-tile (AFR) | 260/192 | OS, DFS | OS(U),1.71 (1.30–2.25) | Crude | Median 28 |
OS(M),1.63 (1.16–2.30) | Crude | ||||||||||||
DFS(U),1.60 (1.28–2.00) | Crude | ||||||||||||
DFS(M),1.45 (1.14–1.88) | Crude | ||||||||||||
Chen et al. [29] | 2018 | China | NSCLC | 529 | I–III (AJCC) | Retrospective | Surgical resection | 9.67 by ROC (AFR) | 392/137 | OS, DFS | OS(U),4.22 (2.83–6.29) | Crude | Median 35.0 (1–78.5) |
OS(M),1.95 (1.21–3.16) | Crude | ||||||||||||
DFS(U),2.73 (2.06–3.62) | Crude | ||||||||||||
DFS(M),1.78 (1.27–2.51) | Crude | ||||||||||||
Gao et al. [30] | 2018 | China | ESCC | 153 | 0–III (AJCC) | Prospective | Surgical resection | 9.3 by ROC (AFR) | 128/25 | OS | OS(U),1.95 (1.18–3.25) | Crude | More than 36 |
OS(M),2.38 (1.15–4.93) | Crude | ||||||||||||
Li et al. [31] | 2018 | China | Lung cancer | 412 | I–IV | Prospective | Multiple modality | 7.8 by ROC (AFR) | NR | OS | OS(U),1.97 (1.36–2.85) | Crude | More than 36 |
OS(M),1.79 (1.23–2.61) | Crude | ||||||||||||
Sun et al. [32] | 2018 | China | Colorectal cancer | 702 | I–III (AJCC) | Prospective | Surgical resection | 9.2 by X-tile (AFR) | 562/118 | OS | OS(U),1.88 (1.25–2.84) | Crude | More than 36 |
OS(M),1.41 (0.90–2.20) | Crude | ||||||||||||
Liang et al. [33] | 2018 | China | Soft tissue sarcoma | 310 | IA–IV (AJCC) | Retrospective | Surgical resection | 13.77 by ROC (AFR) | 176/134 | OS, DFS | OS(U),3.15 (2.07–4.79) | Crude | Median 91.5 |
OS(M),1.91 (1.16–3.13) | Crude | ||||||||||||
DFS(U),1.96 (1.41–2.72) | Crude | ||||||||||||
Xu et al. [34] | 2018 | China | HCC | 151 | 0-C (BCLC) | Retrospective | Surgical resection | 16.1 by ROC (AFR) | 50/101 | OS, DFS | OS(U),2.15 (1.35–3.40) | Crude | Median 33.8 (1–86) |
OS(M),2.02 (1.27–3.21) | Crude | ||||||||||||
DFS(U),1.70 (1.14–2.54) | Crude | ||||||||||||
DFS(M),1.56 (1.03–2.35) | Crude | ||||||||||||
Sun et al. [35] | 2018 | China | ESCC | 373 | I–III (AJCC) | Retrospective | Surgical resection | Score = 0 (AFR) | 154/219 | OS, DFS | OS(U),1.69 (1.27–2.24) | Crude | Median 51.9 |
OS(M),1.37 (1.01–1.88) | Crude | ||||||||||||
DFS(U),1.68 (1.28–2.20) | Crude | ||||||||||||
DFS(M),1.39 (1.04–1.88) | Crude | ||||||||||||
Xu et al. [36] | 2018 | China | Gallbladder cancer | 154 | 0–IVB (AJCC) | Retrospective | Surgical resection | 12.5 by ROC (AFR) | 71/83 | OS | OS(U),4.63 (2.99–7.17) | Crude | Median 17 |
OS(M),2.81 (1.77–4.48) | Crude | ||||||||||||
Zou et al. [37] | 2018 | China | Leukemia | 191 | A–C (Binet stage) | Retrospective | Untreated | 9.7 by X-tile (AFR) | 171/20 | OS | OS(U),3.65 (1.67–7.99) | Crude | Median 51 (1–270) |
OS(M),3.47 (1.54–7.82) | Crude | ||||||||||||
PFS (U),1.24 (0.72–2.13) | Crude | ||||||||||||
Zhang et al. [38] | 2017 | China | Gastric cancer | 360 | II–III (AJCC) | Retrospective | Surgical resection | 8.9 by X-tile (AFR) | 290/70 | OS | OS(U),2.34 (1.59–3.45) | Crude | More than 36 |
OS(M),1.54 (1.01–2.34) | Crude | ||||||||||||
Hwang et al. [39] | 2017 | Korea | Breast cancer | 793 | I–III (AJCC) | Retrospective | Surgical resection | 14.08 by ROC (AFR) | 538/255 | OS | OS(U),2.72 (1.66–4.47) | Crude | Median 44.0 (0–197) |
OS(M),2.62 (1.46–4.72) | Crude | ||||||||||||
Tan et al. [40] | 2017 | China | ESCC | 1135 | T1-4aN0-3 (AJCC) | Retrospective | Surgical resection | 12.5 by X-tile (AFR) | 625/510 | OS | OS(U),1.38 (1.22–1.56) | Curve | More than 60 |
OS(M),1.33 (1.09–1.69) | Crude | ||||||||||||
Zhang et al. [41] | 2019 | China | HCC | 230 | A–C (BCLC) | Prospective | Surgical resection | 15.6 by X-tile (FPR) | NR | OS, DFS | OS(U),5.07 (2.55–10.06) | Crude | More than 36 |
OS(M),4.16 (2.06–8.39) | Crude | ||||||||||||
DFS(U),2.20 (1.36–3.57) | Crude | ||||||||||||
DFS(M),1.77 (1.04–2.99) | Crude | ||||||||||||
Li [42] | 2019 | China | NSCLC | 360 | IIB–IV (AJCC) | Retrospective | Chemotherapy | 21.24 by ROC (FPR) | 151/209 | OS | OS(U),2.09 (1.66–2.62) | Data | 3–45 |
OS(M),1.22 (1.04–1.43) | Crude | ||||||||||||
Du et al. [27] | 2019 | China | Gallbladder cancer | 220 | Metastatic | Retrospective | Chemotherapy mainly | 31.84 by X-tile (FPR) | NR | OS | OS(U),1.93 (1.26–2.97) | Crude | More than 36 |
OS(M),1.57 (1.00–2.46) | Crude | ||||||||||||
Sun et al. [32] | 2018 | China | Colorectal cancer | 555 | I–III (AJCC) | Prospective | Surgical resection | 18.3 by X-tile (FPR) | 230/325 | OS | OS(U),2.40 (1.57–3.67) | Crude | More than 36 |
OS(M),1.94 (1.24–3.05) | Crude | ||||||||||||
Zhang et al. [38] | 2017 | China | Gastric cancer | 360 | II–III (AJCC) | Retrospective | Surgical resection | 12.1 by X-tile (FPR) | 246/114 | OS | OS(U),3.37 (2.02–5.64) | Crude | More than 36 |
OS(M),2.33 (1.37–3.94) | Crude | ||||||||||||
Chen et al. [22] | 2019 | China | Colorectal cancer | 430 | Metastatic | Prospective | Mixed modality but targeted therapy | 22.8 by X-tile (FPR) | NR | OS | OS(U),2.33 (1.42–3.82), Cohort 1 | Crude | More than 36 |
OS(M),1.90 (1.10–3.28), Cohort 1 | Crude | ||||||||||||
Chen et al. [22] | 2019 | China | Colorectal cancer | 77 | Metastatic | Prospective | Radiochemotherapy | 22.8 by X-tile (FPR) | NR | OS | OS(U),4.47 (1.65–12.14), Cohort 2 | Crude | More than 36 |
OS(M),4.21 (1.16–15.27), Cohort 2 | Crude | ||||||||||||
Zhang et al [24] | 2019 | China | Colorectal cancer | 71 | Metastatic | Retrospective | Chemotherapy | 18.49 by ROC (FPR) | 23/48 | PFS | PFS(U),1.79 (1.11–2.88) | Crude | Median 6.67 (1.86–27.17) |